Nikhil Khushalani, M.D.
H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nikhil Khushalani, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:17 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02032810 · Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Melanoma, Skin Cancer · principal investigator
- Ph2NCT01437605 · Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LCH. Lee Moffitt Cancer Center and Research Institute · terminated · Melanoma · principal investigator
- Ph1NCT01176474 · Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaH. Lee Moffitt Cancer Center and Research Institute · completed · Melanoma (Skin) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.